Citius Oncology (CTOR) Restructuring Costs (2023 - 2026)

Citius Oncology (CTOR) has 4 years of Restructuring Costs data on file, last reported at $567937.0 in Q1 2026.

• On a quarterly basis, Restructuring Costs changed 0.0% year-over-year to $567937.0 in Q1 2026; TTM through Mar 2026 was $2.1 million, a 35.83% decrease from a year earlier, with the FY2025 full-year figure at $2.2 million, up 19.26% from the prior year.
• Restructuring Costs for Q1 2026 stood at $567937.0, up from $497937.0 in the prior quarter.
• Over the last five years, Restructuring Costs for CTOR reached as high as $1.3 million in Q2 2024 and fell as low as $30000.0 in Q1 2023.
• Historically, Restructuring Costs has averaged $502161.5 across 4 years, with a median of $532937.0 in 2024.
• Across the five-year window, Restructuring Costs soared 4334.55% in 2024 and sank 57.31% in 2025, its largest moves.
• Year by year, Restructuring Costs stood at $422282.0 in 2023, then surged by 34.49% to $567937.0 in 2024, then retreated by 12.33% to $497937.0 in 2025, then advanced by 14.06% to $567937.0 in 2026.
• Per Business Quant data, the three most recent Restructuring Costs figures were $567937.0 in Q1 2026, $497937.0 in Q4 2025, and $497931.0 in Q3 2025.